3,4-Methylenedioxy-N-ethylamphetamine

3,4-Methylenedioxy-N-ethylamphetamine
Clinical data
Other names	MDEA, MDE, Eve
Routes of; administration	Oral, insufflation, injection, rectal
ATC code	none;
Legal status
Legal status	AU: S9 (Prohibited substance); BR: Class F2 (Prohibited psychotropics); CA: Schedule I; DE: Anlage I (Authorized scientific use only); UK: Class A; US: Schedule I; UN: Psychotropic Schedule I;
Pharmacokinetic data
Metabolism	Hepatic including CYP2D6 and CYP3A4
Onset of action	20–85 minutes
Elimination half-life	(R)-MDEA: 7.5 ± 2.4 hours; (S)-MDEA: 4.2 ± 1.4 hours
Excretion	Renal
Identifiers
	IUPAC name 1-(1,3-Benzodioxol-5-yl)-N-ethylpropan-2-amine;
CAS Number	82801-81-8;
PubChem CID	105039;
ChemSpider	94775;
UNII	ML1I4KK67B;
KEGG	C22717;
ChEBI	CHEBI:132237;
CompTox Dashboard (EPA)	DTXSID70860971 ;
ECHA InfoCard	100.231.031
Chemical and physical data
Formula	C12H17NO2
Molar mass	207.273 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNC(C)Cc1ccc2OCOc2c1;

3,4-Methylenedioxy-N-ethylamphetamine (MDEA; also called MDE and colloquially, Eve) is an empathogenic psychoactive drug. MDEA is a substituted amphetamine and a substituted methylenedioxyphenethylamine. MDEA acts as a serotonin, norepinephrine, and dopamine releasing agent and reuptake inhibitor.

Possession of MDEA is illegal in most countries. Some limited exceptions exist for scientific and medical research.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.